Intratumor heterogeneity, which fosters tumor evolution, is a key challenge in cancer medicine.
Here, we review data and technologies that have revealed intra-tumor heterogeneity …

Deciphering whether actionable driver mutations are found in all or a subset of tumor cells
will likely be required to improve drug development and precision medicine strategies. We …

Recent studies have revealed extensive genetic diversity both between and within tumours.
This heterogeneity affects key cancer pathways, driving phenotypic variation, and poses a …

As tumors grow, they acquire mutations, some of which create neoantigens that influence
the response of patients to immune checkpoint inhibitors. We explored the impact of …

Background Among patients with non–small-cell lung cancer (NSCLC), data on intratumor
heterogeneity and cancer genome evolution have been limited to small retrospective cohorts. …

The interplay between an evolving cancer and a dynamic immune microenvironment remains
unclear. Here we analyse 258 regions from 88 early-stage, untreated non-small-cell lung …

Remarkable progress in molecular analyses has improved our understanding of the evolution
of cancer cells toward immune escape 1 , 2 , 3 , 4 – 5 . However, the spatial configurations …

Precision medicine requires an understanding of cancer genes and mutational processes,
as well as an appreciation of the extent to which these are found heterogeneously in cancer …

Clear cell renal carcinomas (ccRCCs) can display intratumor heterogeneity (ITH). We
applied multiregion exome sequencing (M-seq) to resolve the genetic architecture and …

The early detection of relapse following primary surgery for non-small-cell lung cancer and
the characterization of emerging subclones, which seed metastatic sites, might offer new …